收藏切换
Reflection on the Evaluation Indicators for Drug Efficacy in Treatment of Kidney Disease
收藏切换
PDF
Na WANG, Jiejing LI, Chongqi TANG, Shuiqiang WANG, Songmei XIE*
Chinese Pharmaceutical Journal | 2024, 59(14) : 1283 - 1287
Less
收藏切换
Chinese Pharmaceutical Journal | 2024, 59(14): 1283-1287
Reflection on the Evaluation Indicators for Drug Efficacy in Treatment of Kidney Disease
Full
Na WANG, Jiejing LI, Chongqi TANG, Shuiqiang WANG, Songmei XIE*
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100163, China
Published: 2024-07-22 doi: 10.11669/cpj.2024.14.003
Outline
收藏切换

OBJECTIVE To discuss technical considerations for the design of efficacy evaluation indicators for drugs used in the treatment of kidney disease. METHODS Based on practical experience in disease characteristics, drug development, and evaluation, technical recommendations were proposed for designing efficacy evaluation indicators for kidney disease treatment drugs. RESULTS and CONCLUSION Renal failure and cardiovascular death are considered as the primary clinical outcomes for evaluating the efficacy of drugs used in kidney disease treatment. Based of the urgent clinical need and slow progression of kidney disease, exploring the selection and application of intermediate/surrogate indicators holds significant clinical value. Some evidence suggests that improvement in estimated glomerular filtration rate (eGFR) slope can partially predict the clinical benefits of treatment on chronic kidney disease (CKD) progression, making it a potential alternative indicator for early or slowly progressing CKD patients in drug trials. The correlation between elevated urinary protein levels and duration with renal function loss in lupus nephritis, membranous nephropathy, and IgA nephropathy indicates their potential for predicting renal outcomes; however, further research evidence is still required. In conclusion, when selecting indicators to evaluate efficacy, scientific design should be based on trial objectives, target population characteristics, drug mechanisms of action, and effect intensity while carefully considering surrogate indicators.

chronic kidney disease  /  glomerular disease  /  efficacy evaluation indicator  /  clinical trial design
Na WANG, Jiejing LI, Chongqi TANG, Shuiqiang WANG, Songmei XIE. Reflection on the Evaluation Indicators for Drug Efficacy in Treatment of Kidney Disease[J]. Chinese Pharmaceutical Journal, 2024 , 59 (14) : 1283 -1287 . DOI: 10.11669/cpj.2024.14.003
Year 2024 volume 59 Issue 14
PDF
156
73
Cite this Article
BibTeX
Article Info
doi: 10.11669/cpj.2024.14.003
  • Receive Date:2024-03-06
  • Online Date:2026-01-14
  • Published:2024-07-22
Article Data
Affiliations
History
  • Received:2024-03-06
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 100163, China
References
Share
https://castjournals.cast.org.cn/joweb/zgyxzz/EN/10.11669/cpj.2024.14.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT